DNLI – Denali Therapeutics Inc.
Denali Therapeutics Inc.DNLI
$19.73Name : Denali Therapeutics Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,162,532,352.00
EPSttm : -1.72
Denali Therapeutics Inc.
$19.73
0.60%$0.12
DNLI — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
10.31
Margin Of Safety %
Put/Call OI Ratio
1.75
EPS Next Q Diff
0.01
EPS Last/This Y
0.76
EPS This/Next Y
-0.07
Price
19.84
Target Price
36.19
Analyst Recom
1.15
Performance Q
-21.45
Upside
-214.0%
Beta
1.07
Ticker: DNLI
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | DNLI | 18.95 | 1.30 | 2.39 | 12115 |
| 2026-10-13 | DNLI | 18.4 | 1.31 | 26.45 | 12247 |
| 2026-10-14 | DNLI | 17.79 | 1.30 | 77.50 | 12278 |
| 2026-10-15 | DNLI | 18.33 | 1.32 | 4.64 | 12391 |
| 2026-10-16 | DNLI | 17.53 | 1.34 | 11.50 | 12523 |
| 2026-10-19 | DNLI | 17.96 | 1.63 | 0.88 | 11659 |
| 2026-10-20 | DNLI | 18.94 | 1.50 | 0.67 | 12192 |
| 2026-10-21 | DNLI | 18.68 | 1.40 | 3.67 | 12648 |
| 2026-10-22 | DNLI | 18.67 | 1.44 | 1.41 | 12815 |
| 2026-10-23 | DNLI | 18.4 | 1.44 | 26.52 | 12965 |
| 2026-10-26 | DNLI | 18.67 | 1.43 | 32.63 | 12995 |
| 2026-10-27 | DNLI | 19.22 | 1.44 | 30.45 | 13091 |
| 2026-10-28 | DNLI | 19.28 | 1.46 | 16.40 | 13163 |
| 2026-10-29 | DNLI | 19.34 | 1.48 | 137.82 | 13279 |
| 2026-10-30 | DNLI | 18.94 | 1.52 | 9.75 | 13518 |
| 2026-11-02 | DNLI | 18.86 | 1.56 | 44.50 | 13754 |
| 2026-11-03 | DNLI | 19.49 | 1.58 | 39.30 | 13860 |
| 2026-11-04 | DNLI | 20.95 | 1.62 | 16.86 | 14360 |
| 2026-11-05 | DNLI | 19.71 | 1.68 | 29.32 | 14435 |
| 2026-11-06 | DNLI | 20.05 | 1.67 | 31.46 | 14413 |
| 2026-11-09 | DNLI | 20.34 | 1.71 | 2.96 | 14688 |
| 2026-11-10 | DNLI | 19.84 | 1.75 | 2.68 | 14893 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | DNLI | 18.96 | 50.6 | - | -2.22 |
| 2026-10-13 | DNLI | 18.40 | 50.6 | - | -2.22 |
| 2026-10-14 | DNLI | 17.85 | 50.6 | - | -2.22 |
| 2026-10-15 | DNLI | 18.33 | 50.6 | - | -2.22 |
| 2026-10-16 | DNLI | 17.61 | 50.5 | - | -2.22 |
| 2026-10-19 | DNLI | 18.04 | 50.5 | - | -2.22 |
| 2026-10-20 | DNLI | 18.04 | 50.5 | - | -2.22 |
| 2026-10-21 | DNLI | 18.93 | 50.5 | - | -2.23 |
| 2026-10-22 | DNLI | 18.68 | 50.5 | - | -2.23 |
| 2026-10-23 | DNLI | 18.41 | 50.5 | - | -2.23 |
| 2026-10-26 | DNLI | 18.67 | 50.5 | - | -2.23 |
| 2026-10-27 | DNLI | 19.22 | 50.5 | - | -2.23 |
| 2026-10-28 | DNLI | 19.29 | 50.5 | - | -2.23 |
| 2026-10-29 | DNLI | 19.33 | 50.5 | - | -2.23 |
| 2026-10-30 | DNLI | 18.94 | 50.5 | - | -2.23 |
| 2026-11-02 | DNLI | 18.86 | 50.5 | - | -2.23 |
| 2026-11-03 | DNLI | 19.49 | 50.5 | - | -2.23 |
| 2026-11-04 | DNLI | 20.94 | 50.5 | - | -2.23 |
| 2026-11-05 | DNLI | 19.72 | 50.5 | - | -2.23 |
| 2026-11-06 | DNLI | 20.06 | 22.3 | - | -2.05 |
| 2026-11-09 | DNLI | 20.35 | 22.3 | - | -2.05 |
| 2026-11-10 | DNLI | 19.84 | 15.7 | - | -2.21 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | DNLI | -0.18 | 2.31 | 10.33 |
| 2026-10-13 | DNLI | -0.18 | 2.31 | 10.33 |
| 2026-10-14 | DNLI | -0.18 | 2.31 | 10.33 |
| 2026-10-15 | DNLI | -0.18 | 2.31 | 10.33 |
| 2026-10-16 | DNLI | -0.18 | 2.31 | 10.33 |
| 2026-10-19 | DNLI | -0.18 | 2.32 | 10.33 |
| 2026-10-20 | DNLI | -0.18 | 2.32 | 10.33 |
| 2026-10-21 | DNLI | -0.18 | 2.32 | 10.33 |
| 2026-10-22 | DNLI | -0.18 | 2.32 | 10.33 |
| 2026-10-23 | DNLI | -0.18 | 2.32 | 10.33 |
| 2026-10-26 | DNLI | -0.18 | 2.36 | 10.33 |
| 2026-10-27 | DNLI | -0.18 | 2.36 | 10.34 |
| 2026-10-28 | DNLI | -0.18 | 2.36 | 10.34 |
| 2026-10-29 | DNLI | -0.18 | 2.36 | 10.34 |
| 2026-10-30 | DNLI | -0.18 | 2.36 | 10.34 |
| 2026-11-02 | DNLI | -0.18 | 2.27 | 10.34 |
| 2026-11-03 | DNLI | -0.18 | 2.27 | 10.34 |
| 2026-11-05 | DNLI | -0.18 | 2.27 | 10.34 |
| 2026-11-06 | DNLI | -0.18 | 2.27 | 10.34 |
| 2026-11-09 | DNLI | -0.18 | 1.50 | 10.31 |
| 2026-11-10 | DNLI | -0.18 | 1.50 | 10.31 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.64
Avg. EPS Est. Current Quarter
-0.62
Avg. EPS Est. Next Quarter
-0.64
Insider Transactions
-0.18
Institutional Transactions
1.5
Beta
1.07
Average Sales Estimate Current Quarter
31
Average Sales Estimate Next Quarter
39
Fair Value
Quality Score
22
Growth Score
26
Sentiment Score
79
Actual DrawDown %
63.2
Max Drawdown 5-Year %
-78.3
Target Price
36.19
P/E
Forward P/E
PEG
P/S
148.82
P/B
3.43
P/Free Cash Flow
EPS
-1.74
Average EPS Est. Cur. Y
-2.21
EPS Next Y. (Est.)
-2.28
Target Price Estimates Raised
2
Target Price Estimates Lowered
Profit Margin
-1470.5
Relative Volume
0.6
Return on Equity vs Sector %
-60.2
Return on Equity vs Industry %
-40.5
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
◆
DNLI
Healthcare
$19.85
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
51.9
Range 1M
52.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
41%
EPS NY
-28.8%
52W%
38.7%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+82.3% upside
Upside
+82.3%
Quality
22
DNLI — P/E HistoricalBiotechnology
Denali Therapeutics Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 503
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
DNLI
Latest News
—
Caricamento notizie per DNLI…
stock quote shares DNLI – Denali Therapeutics Inc. Stock Price stock today
news today DNLI – Denali Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch DNLI – Denali Therapeutics Inc. yahoo finance google finance
stock history DNLI – Denali Therapeutics Inc. invest stock market
stock prices DNLI premarket after hours
ticker DNLI fair value insiders trading